Ammonia N 13
Generic: AMMONIA N-13
Basic Information
Manufacturer
Ionetix Corporation
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
INTRAVENOUS
FDA Set ID
61e196ba-3812-4ffd-8032-12b215378fef
Indications & Usage
1 INDICATIONS AND USAGE Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease ( 1 ).
Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease ( 1 ).
Adverse Reactions
6 ADVERSE REACTIONS No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems.
However, the completeness of these sources is not known.
No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system ( 6 ).
To report SUSPECTED ADVERSE REACTIONS, contact Ionetix Corporation at 517-252-4069 x810 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
However, the completeness of these sources is not known.
No adverse reactions have been reported for Ammonia N 13 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system ( 6 ).
To report SUSPECTED ADVERSE REACTIONS, contact Ionetix Corporation at 517-252-4069 x810 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.